Publications by authors named "Jiaxi Mao"

Article Synopsis
  • ADAR1 is an RNA-editing enzyme that shows varying expression across different cancer types, especially lower in certain kidney cancers and higher in liver cancer compared to normal tissues.
  • Validation techniques, including RT-PCR and western blotting, confirmed these expression patterns and their correlation with patient prognosis in kidney and liver cancers.
  • The study identified distinct relationships between ADAR1 expression and specific stromal cell types, notably revealing inverse relationships with the gene claudin-5 in kidney and liver cancer samples.
View Article and Find Full Text PDF
Article Synopsis
  • * Lymphatic endothelial cells (LECs) and blood endothelial cells (BECs) are crucial not just for structural support but also for processes like blood vessel formation (angiogenesis), lymph vessel formation (lymphangiogenesis), and immune response modulation.
  • * The review focuses on the intricate interactions between LECs, BECs, and tumor cells, highlighting their roles in HCC and proposing future research and treatment avenues based on the immune functions of these endothelial cells.
View Article and Find Full Text PDF

Non-alcoholic fatty liver disease (NAFLD) is a complex disease characterized by a massive accumulation of lipids in the liver, with a continuous progression of simple steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Non-alcoholic fatty liver disease is associated with obesity, insulin resistance, and metabolic syndrome; it is a severe public health risk and is currently the most common liver disease of the world. In addition to the fatty infiltration of the liver in non-alcoholic fatty liver disease patients, the field of liver transplantation faces similar obstacles.

View Article and Find Full Text PDF

This study aimed to provide diagnostic clues for patients with elevated serum alpha-fetoprotein (AFP) in the absence of liver tumors and rectify some previously confused concepts about hepatoid carcinoma of the lung through a systematic review on hepatoid adenocarcinoma of the lung (HAL). A thorough search for original articles on HAL published prior to November 2020 was performed using the PubMed, EBSCOhost, Embase, WanFang Data, and China National Knowledge Infrastructure (CNKI) databases. Ninety-four patients from 88 studies met the eligibility criteria.

View Article and Find Full Text PDF

Aims: To evaluate risk of adverse events (AEs) in advanced hepatocellular carcinoma (AHCC) with immune checkpoint therapy in this setting.

Methods: A systematic search of original articles published until November 2019 was performed using PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. And a meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

View Article and Find Full Text PDF

Background: With a novel finding of significantly lower incidence of acute rejection (AR) in patients with hepatocellular carcinoma (HCC) after liver transplantation, compared with those with benign end-stage liver disease (BESLD), in a large national cohort, we analyzed the correlations among the perioperative immuno-inflammation status, postoperative AR, and prognosis in HCC and BESLD patients with same etiology of hepatitis B virus (HBV), who underwent liver transplantation.

Methods: Patients who underwent liver transplantation due to HBV-related HCC or BESLD and experienced AR between September 2008 and April 2017 were analyzed retrospectively and followed up until April 2018. HCC patients with AR were matched with those without AR according to tumor stage and immunosuppressant concentration, at a 1:3 ratio.

View Article and Find Full Text PDF

MicroRNAs (miRNAs) participate in tumorigenesis, progression, recurrence and drug resistance of hepatocellular carcinoma (HCC). However, few miRNAs have been identified and entered clinical practice. Herein, we report that miR-29a is downregulated in tumor-initiating cells (T-ICs) and has an important function in liver T-ICs.

View Article and Find Full Text PDF

Background: Hepatic epithelioid angiomyolipoma (HEAML) is a rare liver disease and is easily misdiagnosed. Enhanced recognition of HEAML is beneficial to the differential diagnosis of rare liver diseases.

Case Summary: We presented two cases of HEAML in Changzheng Hospital, Naval Medical University, and then collected and analyzed all reports about HEAML recorded in PubMed, MEDLINE, China Science Periodical Database, and VIP database from January 2000 to March 2018.

View Article and Find Full Text PDF